Scand J Work Environ Health. 2016;42(6):538-546. doi:10.5271/sjweh.3586

Breast cancer incidence among female flight attendants: exposure-response analyses

By Lynne E Pinkerton, MD, MPH,¹ Misty J Hein, PhD,² Jeri L Anderson, PhD, ¹ Mark P Little, DPhil,³ Alice J Sigurdson, PhD,³ Mary K Schubauer-Berigan, PhD ¹

Pinkerton LE, Hein MJ, Anderson JL, Little MP, Sigurdson AJ, Schubauer-Berigan MK. Breast cancer incidence among female flight attendants: exposure–response analyses. *Scand J Work Environ Health*. 2016;42(6):538–546. doi:10.5271/sjweh.3586

Objective The aim of this study was to examine the association of breast cancer incidence with cosmic radiation dose and circadian rhythm disruption in a cohort of 6093 US female flight attendants.

Methods The association of breast cancer risk with cumulative cosmic radiation dose, time spent working during the standard sleep interval, and time zones crossed (all lagged by ten years), adjusted for non-occupational breast cancer risk factors, was evaluated using Cox regression. Individual exposure estimates were derived from work history data and domicile- and era-specific exposure estimates. Breast cancers were identified from telephone interviews and state cancer registries, and covariate data were obtained from telephone interviews.

Results Breast cancer incidence in the overall cohort was not associated with exposure. Positive associations in breast cancer incidence were observed with all three exposures only among the 884 women with parity of \geq 3. Adjusted excess relative risks for women with parity of \geq 3 were 1.6 [95% confidence interval (95% CI) 0.14–6.6], 0.99 (95% CI -0.04–4.3), and 1.5 (95% CI 0.14–6.2) per 10 mGy, per 2000 hours spent working in the standard sleep interval, and per 4600 time zones crossed (the approximate means of the fourth exposure quintiles among breast cancer cases), respectively.

Conclusions Positive exposure—response relations, although observed only in a small subset of the cohort, were robust. Future studies of breast cancer incidence among other workers with circadian rhythm disruption should assess interaction with parity to see if our findings are confirmed.

Key terms airline attendant; circadian rhythm disruption; cohort study; cosmic ionizing radiation

Studies suggest that flight attendants have an increased incidence of breast cancer compared to the general population (1, 2). However, the reason is unclear. Flight attendants may be at an increased risk of breast cancer because of workplace exposure to elevated levels of cosmic radiation or circadian disruption from traveling across multiple time zones and working at night (3) or because of difference in non-occupational risk factors for breast cancer, such as parity and age at first birth, which may be associated with work as a flight attendant.

We previously reported that parity and age at first

birth may largely explain an observed excess in breast cancer incidence among a large cohort of US female flight attendants formerly employed by Pan American World Airways (Pan Am) (4). Breast cancer incidence was not significantly associated with cosmic radiation dose or measures of circadian rhythm disruption [cumulative time zones crossed and cumulative time spent working during the standard sleep interval (SSI); ie, between 22:00–08:00 hours at the flight attendant's home base domicile] except among women with parity of ≥3. However, we only considered three potential confounders or effect modifiers

Correspondence to: Lynne E Pinkerton, MD, MPH, Industrywide Studies Branch, Division of Surveillance, Hazard Evaluations, and Field Studies, National Institute for Occupational Safety and Health, 1090 Tusculum Ave., R-15, Cincinnati, OH 45226, USA. [E-mail: lep5@cdc.gov]

Industrywide Studies Branch, Division of Surveillance, Hazard Evaluations, and Field Studies, National Institute for Occupational Safety and Health, Cincinnati, OH, USA.

² CACI, Inc, Cincinnati, OH, USA.

Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

(parity, age at first birth, and family history of breast cancer) by stratification, and we did not consider these potential confounders simultaneously, nor did we conduct quantitative exposure–response modeling.

In the current study, we further examined associations of breast cancer incidence in this cohort by considering a wider range of potential confounders and effect modifiers, time windows of exposure, and various model forms. This is the first large cohort study of breast cancer in flight attendants with comprehensive data on non-occupational risk factors for breast cancer.

Methods

Cohort description

The study cohort is a subset of a mortality cohort (5) assembled from company personnel records that included 1707 men and 9617 women who worked for ≥1 year as a flight attendant before Pan Am ceased operation in 1991, were US citizens when hired, and worked ≥1 day after 1 January 1953.

The cohort inclusion criteria and follow-up are described in detail elsewhere (4). Briefly, women in the mortality cohort with a last known address in the US (N=9512) or their next-of-kin, if deceased, were invited to participate in the current study by completing a telephone interview or mailed questionnaire. Of those, 6093 (64.4% of eligible women) completed the interview, gave informed consent, and were free from breast cancer at the start of follow-up and thus were included in the study. Data on participants and non-participants are provided in the Appendix, supplementary table S1 (www.sjweh.fi/index.php?page=data-repository).

Interview and cancer registry data

Data on demographics, work history, risk factors for breast cancer, and cancer diagnoses were obtained in the interview. The interview data were supplemented with data on race, education, height, and weight in the company records and used to create analysis variables for covariates as described in the Appendix. Breast cancer cases, including carcinoma in situ, were identified by interview, medical record follow-back for reported cancers, and linkage with cancer registries in six states (California, Florida, New York, Washington, Texas, and Virginia) where many cohort members had been based or lived. Because of the high positive predictive value of self-reported breast cancer (6), all breast cancer cases identified from the interview were included in the analysis except for two that were refuted by medical records.

Exposure assessment

Individual, time-dependent estimates of cosmic radiation absorbed dose, SSI travel, and number of time zones crossed were developed by linking work history data with domicile- and era-specific exposure estimates as described elsewhere (4, 7). Briefly, domicile- and eraspecific absorbed dose rates were derived from flight schedule data and cosmic radiation absorbed dose per flight calculated using the CARI-6P computer program. For most self-respondents, absorbed dose (in mGy without radiation or tissue weighting factors applied) received during work flights while employed as a flight attendant by any airline and commuter flights (flights taken to the domicile to which the flight attendant was assigned) was estimated by linking domicile- and/ or era-specific absorbed dose rates with work history data obtained from interviews. SSI travel and number of time zones crossed were estimated in an analogous way using methods described elsewhere (8, 9). For 195 cohort members without self-reported work history data from interviews, absorbed dose, SSI travel, and number of time zones crossed incurred during employment as a flight attendant at Pan Am and National airlines (which was purchased by Pan Am in 1981) only were estimated as described by Waters et al (9) using work history data obtained from the company records.

Statistical analyses

Full risk sets were created and analyzed in Cox proportional hazards models with an age timescale to evaluate breast cancer risk with the exposure metrics (evaluated one-at-a-time due to high observed correlations) using the SAS PHREG procedure (SAS Institute Inc, Cary, NC, USA) and the Epicure PECAN module (Risk Sciences International, Ontario, Canada). Women were followed from the date the mortality cohort criteria were met or, for those who transferred to Pan Am from National, the transfer date, whichever was later, until the date of death, diagnosis of first breast cancer, or the interview, whichever came first. Risk sets included the case and all cohort members who entered the cohort prior to the case's age at diagnosis and survived without breast cancer to at least that age. Cumulative exposures were lagged by ten years and truncated at the index case's diagnosis age. As is standard in such analysis, women whose exposures lagged to zero were assigned zero cumulative exposure.

Log-linear, power (log-linear model using a log transformation of the exposure variable), and linear excess relative risk (ERR) (10) model forms were considered. Model fit was evaluated using Akaike Information Criterion (AIC) (11) and restricted cubic spline (12) and categorical (cut-points based on exposure quintiles

among cases) models. For power model analyses, one-third of the smallest positive exposure (0.777 μ Gy, 0.018 hours, and 0.028 time zones crossed) was used for exposures that lagged to zero to avoid taking the natural logarithm of zero. Exposure windows defined by age and reproductive periods were also evaluated in log-linear models. Hazard ratios (HR) and ERR were estimated based on maximum partial likelihood, significance tests were based on the likelihood ratio test (LRT), and confidence intervals (CI) were based on the profile likelihood.

All final models were adjusted for age (the time scale) and included one cumulative exposure metric in addition to the following covariates: menarche age, height, alcohol consumption status, parity, age at first birth, menopausal status, hormone replacement therapy use, and family history of breast cancer among first and/or second degree relatives. These covariates were included in the final models regardless of whether they were associated with breast cancer risk in the cohort because they are well-known risk factors for breast cancer. Effect modification for each of these covariates was evaluated separately in models with the best-fitting form by including the appropriate product term and comparing models with and without the product term using the LRT. All remaining covariates were included in the models as potential confounders. Effect modification was evaluated because parity, age at first birth, and family history of breast cancer have been shown to be potential effect modifiers in studies of radiation-induced breast cancer (13), and other covariates in the final models have been shown to be potential effect modifiers in other studies of breast cancer (eg, 14-16). The proportional hazards assumption was then evaluated for each exposure metric by including an interaction term between age and each exposure metric in the final models and testing for significance using the LRT.

Other covariates that were evaluated but not included in the final models because they were not associated with breast cancer in the cohort (P>0.25) and were not significant predictors of breast cancer risk that improved model fit when added one at a time to models with the covariates listed above are shown in table 1.

Finally, sensitivity analyses were conducted to: (i) evaluate alternative lag periods (5, 15, and 20 years), (ii) exclude cohort members for whom interview data were provided by proxy respondents (N=134), (iii) exclude cohort members who had ≥1 self- or proxy-reported diagnostic examinations or radiation treatments before a breast cancer diagnosis that would result in >100 mGy absorbed dose to the breast (N=82), and (iv) include a time-dependent term to indicate cohort members who underwent a hysterectomy without a bilateral oophorectomy before menopause or age 50 years, the mean age of natural menopause in the cohort, whichever was earlier (N=405). The fourth sensitivity analyses was conducted

Table 1. Covariates evaluated in the analysis

Covariate	Fixed variable	Time- dependent variable	Included in final model
Menarche age	✓		✓
Height	✓		✓
Alcohol consumption status ^a		✓	✓
Parity		✓	✓
Age at first birth		✓	✓
Menopausal status		✓	✓
Hormone replacement therapy use a		✓	✓
Family history of breast cancer b	✓		✓
Birth year	✓		
Race/ethnicity	✓		
Education	✓		
Jewish religion c	✓		
Birthplace d	✓		
Body mass index at age 20	✓		
Change in body mass index e	✓		
Cigarette smoking status ^a		✓	
Pack-years of smoking ^a		✓	
Average number of alcoholic drinks per week ^a		✓	
Cumulative number of alcoholic drinks ^a		✓	
Breastfeeding status		✓	
Breastfeeding duration		✓	
Age at menopause		✓	
Age at natural menopause		✓	
Personal history of breast biopsy for benign breast disease	✓		

- ^a Because events leading to a breast cancer diagnosis may have caused some cohort members to stop using cigarettes or alcohol or to discontinue hormone replacement therapy, these variables were lagged by two years.
- b Family history of breast cancer among first and/or second degree relatives.
- c Jewish religion was evaluated because women of Ashkenazi Jewish descent are more likely to have BRCA1 and BRCA2 gene mutations and thus, may have an increased breast cancer risk.
- d Birthplace (westernized country, other) was evaluated because some non-westernized countries have low background rates of breast cancer.
- change in body mass index from age 20 to the date of interview or, if deceased, during the last ten years of life.

because some of these women may have been pre-menopausal but menopausal status was based on whether each subject had a menstrual period within the last 12 months, resulting in possible misclassification for this risk factor. For the power model analysis, sensitivity analyses were also conducted to: (i) use alternative values (the smallest positive exposure or the 0.05 percentile of positive exposures) for exposure estimates that lagged to zero or less than the 0.05 percentile of positive exposures, respectively, and (ii) to add one-third of the smallest positive exposure and these alternative values to all exposures instead of using these values for exposures that lagged to zero or less than the 0.05 percentile of positive exposures. The 0.05 percentile was considered because the minimum positive lagged exposure value was very low compared to other exposure values.

The Institutional Review Boards of the National Institute for Occupational Safety and Health and the National Cancer Institute approved the study.

Results

Descriptive information for the 344 women with breast cancer and 5749 women without breast cancer in the study is shown in table 2. Breast cancer risk in the cohort according to non-occupational factors in the final models is shown in table 3. Breast cancer risk according to other factors that were evaluated but not included in the final models is shown in the Appendix, supplementary table S2 (www.sjweh.fi/index.php?page=data-repository).

The relation of breast cancer incidence with each exposure metric was modified by parity. Results among women with parity of 0, 1, and 2 were similar and nonsignificant (data not shown), so these categories were collapsed, which improved model fit. Results for the linear ERR model, which overall appeared to be best-fitting, are shown in table 4. Significant positive exposure–response relations among women with parity of three or more were observed for absorbed dose and time zones crossed (ERR 1.6 per 10 mGy, 95% CI 0.14-6.6 and 1.5 per 4600 time zones crossed, 95% CI 0.14-6.2, respectively). Similar exposure-response trends were observed for SSI travel (ERR 0.99 per 2000 hours, 95% CI -0.041-4.3), but were not statistically significant. Similar results were obtained for other model forms [see Appendix, supplementary table S3 (www.sjweh.fi/index.php?page=datarepository) and figure 1] and in all sensitivity analyses. HR among women with parity of ≥ 3 were similar across birth windows for absorbed dose and time zones crossed but the HR was higher for time spent working during SSI travel at first birth or later than for SSI travel prior to the first birth. The HR among women with parity of ≥ 3 was higher for all three exposures accrued at age \geq 40 years than for exposures accrued at younger ages, but the CI were wide and overlapped. There was no evidence of effect modification by age at menarche, height, use of hormone replacement therapy, or family history of breast cancer (results not shown). Findings for alcohol consumption status and menopausal status were not robust, but depended on the model form (results not shown; see www.sjweh.fi/index.php?page=data-repository for additional information).

When the proportional hazards assumption was tested in the linear ERR models by including a three-way interaction term for exposure, parity, and age (<50 versus ≥50 years), the interaction terms were not statistically significant. However, the exposure effect among women with parity of ≥3 primarily occurred among women ≥50 years of age (supplementary table S4; results for women with parity <3 not shown, www.sjweh.fi/index.php?page=data-repository). Relatively few cases were observed among women with high parity at younger ages.

A post hoc evaluation of confounding indicated little confounding of the exposure estimates (<15% change

in the exposure coefficient) by any of the covariates in the final models among cohort members with ≥ 3 births; exposure effect estimates among cohort members with fewer than three births were not statistically significant.

Discussion

The current study confirmed our previous findings of unexpected exposure—response relations only in women with high parity. Although based on a small subset (15%) of the cohort, these findings were observed in all model forms and persisted in all sensitivity analyses.

Other epidemiological data suggesting breast cancer incidence in flight attendants is associated with cosmic radiation dose or circadian rhythm disruption are limited. In the only other relatively large study evaluating both exposures (17), breast cancer risk was not associated with cosmic radiation dose after adjusting for parity or with number of flights crossing ≥ 6 time zones after adjusting for parity and age at first birth. None of the previous studies report evaluating effect modification by parity (17–23).

We could not assess the independent associations of cosmic radiation dose and circadian rhythm disruption with breast cancer incidence because the exposure metrics were highly correlated. Although model fits using the AIC criterion were similar for the power and linear ERR models, visually, the power model did not appear to fit well in the low exposure region among women with high parity, and overall the ERR models that are linear in the cumulative exposure D, in which relative risk = $1 + \alpha D$, appeared to be best-fitting. Previous studies have observed a linear relation between breast cancer risk and absorbed dose among other groups of radiation-exposed women (24). However, the ERR per 10 mGy observed in our study among the small subset of women with high parity is two orders of magnitude higher than predicted by the preferred model for breast cancer in BEIR VII (24). The predicted ERR per 10 mGy is 0.02 based on atomic bomb survivor data at an attained age of 50 years, the approximate mean attained age of women in the cohort with breast cancer. In addition, other data indicate that multiple births are associated with a reduction in the increased breast cancer risk associated with radiation exposure (24-26). The large difference between the observed and predicted ERR for women with high parity and the observed pattern of results by parity, which is the opposite of what would be expected for radiation-induced breast cancer, suggest that the observed exposure–response relations, if causal, are probably not due to cosmic radiation exposure but are more likely related to circadian disruption.

We previously speculated that women in our study

Table 2. Characteristics of women with and without breast cancer. [BMI=body mass index; IQR=interquartile range; SSI=standard sleep interval (ie, 22:00–08:00 hours at the flight attendant's home base domicile).]

Characteristic	Breast cancer cases (N=344)				Non-cases (N=5749)					
	N	%	Mean	Median	IQR	N	%	Mean	Median	IQR
Proxy respondent	33	10				101	2			
Year of birth			1943	1944	1939-1947			1949	1947	1944-1954
White, non-Hispanic	303	88				4870	85			
Education										
High school or less	15	4				285	5			
Some college or professional training	112	33				1701	30			
College graduate	143	42				2432	42			
Post-college graduate work	73	21				1324	23			
Unknown	1	<1				7	<1			
Age at menarche (years) ^a			12.8	13	12-13			13.0	13	12-14
Height (cm) ^a			166	165	163-170			166	165	163-170
BMI at age 20 years (kg/m²) a			20	20	19–21			20	20	19-21
BMI change from 20 years (kg/m²) a			3.4	3.0	0.8-5.3			3.5	2.7	1.0-5.1
Ever smoker a, b	183	53				2970	52			
Pack-years among smokers b			15	10	2.3-20			12	6.5	1.6-18
Ever drank alcohol a, b	295	86				4741	82			
Among ever drinkers:										
Average drinks/week b			5.8	4.0	2.0-7.0			5.2	4.0	2.0-7.0
Cumulative drinks b			7500	4500	2000-10000			7400	4400	1800-9600
Parity ^b										
0	124	36				2001	35			
1–2	174	51				2834	49			
≥3	42	12				842	15			
Unknown	4	1				72	1			
Number of births among parous women b			2.0	2.0	1–2			2.0	2.0	1–2
Age at first birth (years) b			30	29	26–33			30	30	27–34
Ever breast-fed, among those with ≥1 live birth(s) ^b	168	78				3044	83			
Age first breast-fed (years) b			31	31	28-34			31	30	28-34
Breastfeeding, weeks b			50	35	18–66			62	48	22-83
Menopausal status b										
Pre-menopausal	135	39				2037	35			
Menopausal – natural	106	31				2539	44			
Menopausal – other	86	25				1050	18			
Unknown/indeterminate	17	5				123	2			
Age at menopause, among menopausal (years) $^{\rm a,b}$			46	48	44–50			48	50	45–52
Hormone replacement therapy b										
Never used	201	58				2878	50			
Current user	79	23				1564	27			
Recent user (quit ≤2 years ago)	37	11				689	12			
Distant user (quit >2 years ago)	15	4				548	10			
Unknown/indeterminate	12	3				70	1			-
Years of use, among ever users b			7.4	6.8	3.0–10			7.5	6.1	3.0-11
Family history of breast cancer in first and/or second degree relative a, b	149	43				1904	33			
History of benign breast disease a, b	68	20		•		944	16			
Age at first exposure (years) °			23	22	22-24			23	22	22-24
Year of first exposure c			1966	1967	1962-1970			1972	1970	1966-1978
Years since first exposure c			36	36	33-41			31	33	25-37
Duration of exposure (years) b, d			11	6.8	3.1-16			12	7.7	3.1-17
Cumulative cosmic radiation absorbed dose (mGy) ^b			10	5.5	2.6–16			12	7.3	2.7–17
Cumulative SSI travel (hours) ^b Cumulative time zones crossed (N) ^b			2000 5000	1300 2700	520–3000 1200–7400			2200 5900	1500 3700	510–3200 1300–8700

^a Age at menarche missing for 270 subjects (including all subjects with proxy respondents), height missing for 1 subject, body mass index missing for 5 subjects, change in body mass index missing for 56 subjects, smoking status missing for 29 subjects, alcohol consumption status missing for 28 subjects, age at menopause missing for 3 subjects, family history of breast cancer missing for 569 subjects, and history of benign breast disease missing for 70 subjects.

^b Cumulative value calculated as of the date of diagnosis for cases and as of the interview date for non-cases.

^c First exposure was based on first employment as a flight attendant in jobs involving flying and thus incurring exposure to cosmic radiation and circadian rhythm disruption.

^d Duration of employment as a flight attendant in jobs involving flying; all participants were employed for one or more years as a flight attendant according to the personnel records, but 24 participants reported less than one year of employment as a flight attendant in jobs involving flying in the interview.

Table 3. Association between reproductive and other factors included in the final models and breast cancer incidence in the cohort. [HR=hazard ratio; 95%CI=95% confidence interval.]

HR a 95% Cl			
 <12 years 1.44 1.01-2.05 12-13 years 1.12 0.86-1.48 ≥14 years 1 Don't know 2.78 1.76-4.30 Height (1 cm increase b) 1.02 1.00-1.04 Alcohol status (lag=2 years) Non-drinker 1 Current 1.18 0.87-1.63 Former 1.50 0.95-2.35 Parity 0, 1, 2 1 ≥3 0.71 0.49-1.00 Age at first birth (years) Nulliparous 1 <30 30-<35 1.14 0.84-1.54 ≥35 1.30 0.90-1.85 Menopausal status Pre-menopausal 1 Natural menopause 1.28 0.92-1.80 Other menopause 1.76 1.25-2.46 Don't know 1.06 0.54-1.95 Hornone replacement therapy use (lag=2 years) Don't know 1.35 0.62-2.66 Never or 2-year lag duration = 0 1 2-year lag duration 3- years 0.70 0.45-1.04 2-year lag duration 7-<10 years 1.50 0.93-2.34 2-year lag duration >10 years 1.50 0.93-2.34 2-year lag duration >20 years 1.50 0.93-2.34 2-year lag duration >20 years 1.65 1.31-2.07 Neither 1 		HR ^a	95% CI
12—13 years ≥14 years Don't know Height (1 cm increase b) Non-drinker Current Former 1.50 Parity 0, 1, 2 ≥3 0.71 Age at first birth (years) Nulliparous 4.30 30—35 Enemopausal status Pre-menopausal Nenopausal status Pre-menopause Other menopause Don't know 1.28 0.30 1.28 0.90—1.85 Menomore selbon't know Newror 2-year lag duration = 0 2-year lag duration ≥10 years 1.50 0.86—1.48 1.76—4.30 1.00—1.04 1.00—1.04 1.08 1.18 0.87–1.63 0.87–1.63 0.87–1.63 0.93–1.63 30—35 1.14 0.84–1.54 235 1.30 0.90–1.85 Menopausal status Pre-menopausel 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 2-year lag duration 3 years 2-year lag duration 3- 0.90 0.45–1.04 2-year lag duration ≥10 years 1.50 0.93–2.34 2-year lag duration ≥10 years 1.65 1.31–2.07 Neither	Age at menarche		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	<12 years	1.44	1.01-2.05
Don't know 2.78 1.76–4.30 Height (1 cm increase $^{\text{b}}$) 1.02 1.00–1.04 Alcohol status (lag=2 years) Non-drinker 1 Current 1.18 0.87–1.63 Former 1.50 0.95–2.35 Parity 0, 1, 2	12-13 years	1.12	0.86-1.48
Height (1 cm increase b) 1.02 1.00-1.04 Alcohol status (lag=2 years) Non-drinker 1 Current 1.18 0.87-1.63 Former 1.50 0.95-2.35 Parity 0, 1, 2 1 ≥3 0.71 0.49-1.00 Age at first birth (years) Nulliparous 1 <30 1.23 0.93-1.63 30-<35 1.14 0.84-1.54 ≥35 1.30 0.90-1.85 Menopausal status Pre-menopausal 1 Natural menopause 1.28 0.92-1.80 Other menopause 1.76 1.25-2.46 Don't know 1.06 0.54-1.95 Hormone replacement therapy use (lag=2 years) Don't know 1.35 0.62-2.66 Never or 2-year lag duration = 0 1 2-year lag duration <3 years 0.70 0.45-1.04 2-year lag duration >3-<7 years 1.01 0.67-1.47 2-year lag duration >10 years 1.50 0.93-2.34 2-year lag duration >10 years 0.90 0.54-1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31-2.07 Neither 1	≥14 years	1	
Alcohol status (lag=2 years) Non-drinker Current 1.18 0.87–1.63 Former 1.50 0.95–2.35 Parity 0, 1, 2 1 23 0.71 Age at first birth (years) Nulliparous 1 <30 1.23 30–<35 1.14 235 1.14 0.84–1.54 235 1.30 0.90–1.85 Menopausal status Pre-menopausal 1 Natural menopause 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) Don't know 1.35 Never or 2-year lag duration = 0 2-year lag duration <3 years 2-year lag duration ≥ 10 years 2-year lag duration ≥ 10 years 1.50 0.93–2.34 2-year lag duration ≥ 10 years 1.01 2-year lag duration ≥ 10 years 1.50 0.93–2.34 2-year lag duration ≥ 10 years 1.65 1.31–2.07 Neither	Don't know	2.78	1.76-4.30
Alcohol status (lag=2 years) Non-drinker Current 1.18 0.87–1.63 Former 1.50 0.95–2.35 Parity 0, 1, 2 1 23 0.71 Age at first birth (years) Nulliparous 1 <30 1.23 30–<35 1.14 235 1.14 0.84–1.54 235 1.30 0.90–1.85 Menopausal status Pre-menopausal 1 Natural menopause 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) Don't know 1.35 Never or 2-year lag duration = 0 2-year lag duration <3 years 2-year lag duration ≥ 10 years 2-year lag duration ≥ 10 years 1.50 0.93–2.34 2-year lag duration ≥ 10 years 1.01 2-year lag duration ≥ 10 years 1.50 0.93–2.34 2-year lag duration ≥ 10 years 1.65 1.31–2.07 Neither	Height (1 cm increase b)	1.02	1.00-1.04
Current 1.18 0.87-1.63 Former 1.50 0.95-2.35 Parity 0,1,2 1 0,1,2 1 0.71 0.49-1.00 Age at first birth (years) Nulliparous 1 <30			
Former 1.50 0.95–2.35 Parity 0, 1, 2 1 ≥3 0.71 0.49–1.00 Age at first birth (years) Nulliparous 1 30–31 30–35 1.23 0.93–1.63 30–35 1.14 0.84–1.54 ≥35 1.30 0.90–1.85 Menopausal status Pre-menopausal 1 Natural menopause 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag–2 years) Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration < 3 years 0.70 0.45–1.04 2-year lag duration 3–<7 years 1.01 0.67–1.47 2-year lag duration >10 years 1.50 0.93–2.34 2-year lag duration >10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31–2.07 Neither 1	Non-drinker	1	
Parity 0, 1, 2	Current	1.18	0.87-1.63
0, 1, 2	Former	1.50	0.95 - 2.35
	Parity		
Age at first birth (years) 1 Nulliparous 1 <30 1.23 0.93–1.63 $30-<35$ 1.14 0.84–1.54 ≥ 35 1.30 0.90–1.85 Menopausal status 1 Natural menopause 1.28 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) 0.01 0.62–2.66 Never or 2-year lag duration = 0 1 1 2-year lag duration < 3 years 0.70 0.45–1.04 2-year lag duration < 3 years 1.01 0.67–1.47 2-year lag duration < 10 years 1.50 0.93–2.34 2-year lag duration < 10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or $< 2^{nd}$ degree relative 1.65 1.31–2.07 Neither 1 1	0, 1, 2	1	
Nulliparous 1	≥3	0.71	0.49-1.00
30	Age at first birth (years)		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Nulliparous	1	
≥35 1.30 0.90–1.85 Menopausal status Pre-menopausal 1 Natural menopause 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration <3 years 0.70 0.45–1.04 2-year lag duration 3–<7 years 1.01 0.67–1.47 2-year lag duration >10 years 1.50 0.93–2.34 2-year lag duration ≥10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31–2.07 Neither 1	<30	1.23	0.93-1.63
Menopausal status 1 Pre-menopausal 1 Natural menopause 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) (lag=2 years) Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration $<$ 3 years 0.70 0.45–1.04 2-year lag duration $<$ 4 years 1.01 0.67–1.47 2-year lag duration $<$ 5 years 1.50 0.93–2.34 2-year lag duration $<$ 10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or $<$ 2nd degree relative 1.65 1.31–2.07 Neither 1 1 1	30-<35	1.14	0.84-1.54
Pre-menopausal 1 Natural menopause 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) 0.62–2.66 Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration 3 –27 years 0.70 0.45–1.04 2-year lag duration 3 –27 years 1.01 0.67–1.47 2-year lag duration 7 –10 years 1.50 0.93–2.34 2-year lag duration \ge 10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31–2.07 Neither 1 1	≥35	1.30	0.90-1.85
Natural menopause 1.28 0.92–1.80 Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) 0.62–2.66 Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration <3 years	Menopausal status		
Other menopause 1.76 1.25–2.46 Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) 0.62–2.66 Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration <3 years	Pre-menopausal	1	
Don't know 1.06 0.54–1.95 Hormone replacement therapy use (lag=2 years) 1.35 0.62–2.66 Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration <3 years	Natural menopause	1.28	0.92-1.80
Hormone replacement therapy use (lag=2 years) Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration <3 years 0.70 0.45–1.04 2-year lag duration 3–<7 years 1.01 0.67–1.47 2-year lag duration 7−<10 years 1.50 0.93–2.34 2-year lag duration ≥10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31–2.07 Neither 1		1.76	1.25-2.46
(lag=2 years) Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 2-year lag duration <3 years 0.70 0.45–1.04 2-year lag duration 3–<7 years 1.01 0.67–1.47 2-year lag duration 7−<10 years 1.50 0.93–2.34 2-year lag duration ≥10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31–2.07 Neither 1	Don't know	1.06	0.54-1.95
Don't know 1.35 0.62–2.66 Never or 2-year lag duration = 0 1 1 2-year lag duration <3 years			
Never or 2-year lag duration = 0 1 2-year lag duration <3 years			
2-year lag duration <3 years 0.70 0.45–1.04 2-year lag duration 3–<7 years 1.01 0.67–1.47 2-year lag duration 7–<10 years 1.50 0.93–2.34 2-year lag duration ≥10 years 0.90 0.54–1.44 Family history of breast cancer 1^{st} and/or 2^{nd} degree relative 1.65 1.31–2.07 Neither 1			0.62–2.66
2-year lag duration 37 years 1.01 0.67-1.47 2-year lag duration 7-<10 years 1.50 0.93-2.34 2-year lag duration ≥10 years 0.90 0.54-1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31-2.07 Neither 1		-	
2-year lag duration 7-<10 years 1.50 0.93-2.34 2-year lag duration ≥10 years 0.90 0.54-1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31-2.07 Neither 1			
2-year lag duration ≥10 years 0.90 0.54–1.44 Family history of breast cancer 1st and/or 2nd degree relative 1.65 1.31–2.07 Neither 1			
Family history of breast cancer 1 st and/or 2 nd degree relative 1.65 1.31-2.07 Neither 1			
$1^{\rm st}$ and/or $2^{\rm nd}$ degree relative 1.65 1.31–2.07 Neither 1		0.90	0.54–1.44
Neither 1			
1.44.41.41	•		1.31–2.07
Don't know 1.18 0.81–1.68		•	
	Don't know	1.18	0.81-1.68

^a HR were estimated from a model that included all of the variables listed in the table and adjusted for age (time scale). Alcohol status, parity, age at first birth, menopausal status, and hormone replacement therapy use were treated as time-dependent variables.

with high parity may have been sleep-deprived from the home environment and therefore more sensitive to the effects of circadian rhythm disruption from work (4). A study that reported a linear increase in self-reported sleep insufficiency with the number of children in the home (27) provides some support for this speculation. In our study, women with high parity were more likely to have worked as a flight attendant after giving birth to a child than women with low parity. In addition, most women (87%) with high parity in the highest quartile of exposure for time zones crossed worked after giving birth to their third child.

Few data exist on effect modification by parity among workers who experience circadian rhythm disruption. In contrast to our study, effect modification by parity was not observed in a study of shift work and breast cancer among women in the Danish military (28). Effect modification by parity could be assessed in other

Table 4. Excess relative risk (ERR) of breast cancer for 10-year lagged cumulative exposure variables stratified by parity (0, 1, 2 versus ≥3 births).^a [AIC=Akaike Information Criterion; 95% CI=profile-likelihood based 95% confidence interval.]

Cumulative AIC exposure			arity 1, 2)		Parity (≥3)	P-value ^b
metric (comparison)		ERR	95% CI	ERR	95% CI	
Absorbed dose 10 mGy increase	5364.405	-0.021	-0.14–0.17	1.6	0.14-6.6	0.02
Standard sleep interval travel 2000 hour increase	5366.195	-0.039	-0.15–0.14	0.99	-0.041–4.3	0.06
Time zones crossed 4600 zone increase	5364.416	-0.0017	-0.12–0.18	1.5	0.14–6.2	0.02

a 6001 subjects including 340 cases were included in the analysis; all models excluded subjects with missing height, alcohol status, or birth information. Results are adjusted for age (since risk sets were created based on attained age), age at menarche, height, alcohol status, age at first birth, menopausal status, use of hormone replacement therapy, and family history of breast cancer (covariate categories are indicated in table 3). The models also included terms for parity, exposure, and the product of parity and exposure. Specifically, under the stratified model, the hazard function for the jth individual in the ith risk set is expressed as $\lambda_{ij}(t) = \lambda_{i0}(t) \exp[Z^i_{ij}\beta]$. For covariates X_1, \ldots, X_p (assume X_p is an indicator of ≥3 births versus 0/1/2 births) and exposure variable X_p , the linear excess risk model is given by $\lambda_{ij}(t) = \lambda_{i0}(t) \exp[\beta_1 X_1 + \ldots + \beta_p X_p]$ (1+ $\beta_e X_e + \beta_{pe} X_p X_g$). For exposure D, the ERR is $\beta_e \times D$ for parity 0/1/2 and the ERR is $(\beta_e + \beta_{pe}) \times D$ for parity ≥3 (where relative risk = 1 + ERR). b P-value for model with two way interaction for exposure and parity

studies of aircrew with data on parity and in other existing studies of workers who experience circadian rhythm disruption. Most studies of breast cancer incidence in flight attendants have little data on potential confounders beyond parity and age at first birth; however, our study suggests that this is not a major limitation.

compared to model without an interaction term.

Some of the observed associations of breast cancer risk with known breast cancer risk factors were unexpected. Former drinkers may have had a higher breast cancer risk than current drinkers because former drinkers drank more alcoholic drinks per week than current drinkers (data not shown). Although most women who used hormone replacement therapy did not have higher breast cancer risk than women who never took hormone replacement therapy according to the multivariable models, risk estimates for women with ≥ 3 years of use (lagged two years) were slightly higher and >1 in bivariate analyses (data not shown). The impact of hormone replacement therapy in the multivariable models may have been partially captured by menopausal status, which was based on whether the subject had a menstrual period in the last 12 months. We did not differentiate combined hormone replacement therapy from estrogen replacement therapy, and this may have also impacted our ability to detect a clear trend between breast cancer

^b The parameter estimate for height (in cm) is 0.021.




Figure 1. Breast cancer hazard ratios from the parity interaction models (curves on the left-hand-side reflect risk among those with <3 births: curves on the right-hand-side reflect risk among those with ≥ 3 births). Horizontal lines represent the quintile model; the solid curve with dots (●) the log-linear model; the dashed curve with squares (**I**) the power model; the solid curve with diamonds (◆) the spline model; and the dashed curve with triangles (A) the excess relative risk model. Hazard ratios are adjusted for attained age, age at menarche, height, alcohol use, age at first birth, menopausal status, hormone replacement therapy use and family history of breast cancer and are normalized to the mean (0.78 mGy of absorbed dose, 150 hours of standard sleep interval travel, and 360 time zones crossed) of the baseline group in the categorical models. The models also included terms for parity, exposure, and the product of parity and exposure. [SSI=standard sleep interval.]

risk and duration of use. The unexpected results for age at first birth may be related to the observed occupational exposure effect modification by parity in conjunction with the correlation between parity and age at first birth. Breast cancer risk was not associated with body mass index in our study. However, the low mean body mass index and narrow distribution in the cohort, which reflect historically stringent height and weight requirements for employment as a flight attendant, limited our ability to detect an association.

Concluding remarks

Breast cancer incidence was not associated with estimates of cumulative cosmic radiation dose or measures of circadian rhythm disruption except among the small subset of women with high parity. If causal, the associations observed in high parity women seem more likely to be from circadian rhythm disruption than cosmic radiation. However, cautious interpretation of the findings in high parity women is warranted, and we recommend further study of breast cancer incidence among workers

with circadian rhythm disruption to see if our findings are confirmed. Limitations of our previous analyses (low cumulative exposure, potential exposure misclassification, potential recall bias, relatively low participation) remain (4).

Acknowledgements

We thank the members of the Pan Am flight attendant cohort and their families for participating in this study. We acknowledge and thank the National Death Index; Health Statistics Section of the Colorado Department of Public Health and Environment; Connecticut Department of Public Health (DPH); Florida Department of Health; Office of Vital Statistics, New York City Department of Health; New York State Department of Health; Texas Department of State Health Services; and other state vital statistics offices for providing death data and death certificates for the study and the following organizations that provided cancer registry data: California Cancer Registry, California Department of Public Health; Florida Cancer Data System; New York State Cancer Registry, New York Department of Health; Texas Cancer Registry, Texas Department of State Health Services; Virginia Cancer Registry, Virginia Department of Health; Washington State Cancer Registry, Washington Department of Health. We also thank current and former NIOSH staff and contractors for their contributions to the collection, coding, and management of study data.

The study was funded, in part, by an interagency agreement with the National Cancer Institute and by the Office of Women's Health of the US Department of Health and Human Services. The research was also supported in part by the intramural research programs of the Division of Cancer Epidemiology and Genetics, National Cancer Institute and the National Institute for Occupational Safety and Health.

Disclaimers

Data were supplied by the Health Statistics Section of the Colorado Department of Public Health and Environment, which specifically disclaims responsibility for any analyses, interpretations, or conclusions it has not provided. This study was approved by the Connecticut DPH Health Investigations Committee. Certain data used in this report were obtained from the Connecticut DPH. The authors assume full responsibility for analyses and interpretation of these data. The information contained herein was also derived, in part, from data provided by the Office of Vital Statistics, New York City Depart-

ment of Health. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute: and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended nor should be inferred. The Florida cancer incidence data used in this report were collected by the Florida Cancer Data System (FCDS) under contract with the Florida Department of Health (FDOH). The views expressed herein are solely those of the authors and do not necessarily reflect those of the FCDS or FDOH. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

The authors declare no conflicts of interest.

References

- Buja A, Mastrangelo G, Perissinotto E, Grigoletto F, Frigo AC, Rausa G, et al. Cancer incidence among female flight attendants: a meta-analysis of published data. J Womens Health. 2006;15:98-105. http://dx.doi.org/10.1089/ jwh.2006.15.98
- Pukkala E, Helminen M, Haldorsen T, Hammar N, Kojo K, Linnersjö A, et al. Cancer incidence among Nordic airline cabin crew. Int J Cancer. 2012;131:2886-2897. http://dx.doi. org/10.1002/ijc.27551
- International Agency for Research on Cancer (IARC). IARC
 monographs on the evaluation of carcinogenic risks to humans:
 painting, firefighting, and shiftwork. Lyon: IARC; 2010. IARC
 monographs on the evaluation of carcinogenic risks to humans,
 vol 98.
- Schubauer-Berigan MK, Anderson JL, Hein MJ, Little MP, Sigurdson AJ, Pinkerton LE. Breast cancer incidence in a cohort of U.S. flight attendants. Am J Ind Med. 2015;58:252– 266. http://dx.doi.org/10.1002/ajim.22419
- Pinkerton LE, Waters MA, Hein MJ, Zivkovich Z, Schubauer-Berigan MK, Grajewski B. Cause-specific mortality among a

- cohort of U.S. flight attendants. Am J Ind Med. 2012;55:25-36. http://dx.doi.org/10.1002/ajim.21011
- Bergmann MM, Calle EE, Mervis CA, Miracle-McMahill HL, Thun MJ, Heath CW. Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol. 1998;147:556-562. http:// dx.doi.org/10.1093/oxfordjournals.aje.a009487
- Anderson JL, Waters MA, Hein MJ, Schubauer-Berigan MK, Pinkerton LE. Assessment of cosmic radiation exposure of female flight attendants using questionnaire data. Aviat Space Environ Med. 2011;82:1049-1054. http://dx.doi.org/10.3357/ ASEM.3091.2011
- Grajewski B, Nguyen MM, Whelan EA, Cole RJ, Hein MJ. Measuring and identifying large-study metrics for circadian rhythm disruption in female flight attendants. Scand J Work Environ Health. 2003;29:337-346. http://dx.doi.org/10.5271/ sjweh.740
- Waters MA, Grajewski B, Pinkerton LE, Hein MJ, Zivkovich Z. Development of historical exposure estimates of cosmic radiation and circadian rhythm disruption for cohort studies of Pan Am flight attendants. Am J Ind Med. 2009;52:751-761. http://dx.doi.org/10.1002/ajim.20738
- Langholz B, Richardson DB. Fitting general relative risk models for survival time and matched case-control analysis. Am J Epidemiol. 2010;171:377-383. http://dx.doi. org/10.1093/aje/kwp403
- Akaike, H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN and Czáki F, editors. 2nd International Symposium on Information Theory. Budpest: Akadémiai Kiadó; 1973. p267-281.
- Harrell FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer Verlag, Inc.; 2001. http://dx.doi.org/10.1007/978-1-4757-3462-1
- Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res. 2005;7:21-32. http://dx.doi.org/10.1186/bcr970
- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578. http://dx.doi.org/10.1016/S0140-6736(08)60269-X
- Pizot C, Boniol M, Mullie P, Koechlin A, Boniol M, Boyle P, et al. Physical activity, hormone replacement therapy and breast cancer risk: a meta-analysis of prospective studies. Eur J Cancer. 2016;52:138-154. http://dx.doi.org/10.1016/j.ejca.2015.10.063
- Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Kathleen Cuningham Consortium for Research into Familial Breast Cancer, et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010;124:441-451. http://dx.doi.org/10.1007/s10549-010-0842-y
- 17. Pukkala E, Helminen M, Haldorsen T, Hammar N, Kojo K, Linnersjö A, et al. Cancer incidence among Nordic airline

- cabin crew. Int J Cancer 2012;131:2886-2897. http://dx.doi.org/10.1002/jjc.27551
- Haldorsen T, Reitan JB, Tveten U. Cancer incidence among Norwegian airline cabin attendants. Int J Epidemiol. 2001;30:825-830. http://dx.doi.org/10.1093/ije/30.4.825
- Kojo K, Pukkala E, Auvinen A. Breast cancer risk among Finnish cabin attendants: a nested case-control study. Occup Environ Med. 2005;62:488-493. http://dx.doi.org/10.1136/ oem.2004.014738
- Rafinsson V, Sulem P, Tulinius H, Hrafnkelsson J. Breast cancer risk in airline cabin attendants: a nested case-control study in Iceland. Occup Environ Med. 2003;60:807-809. http://dx.doi. org/10.1136/oem.60.11.807
- Linnersjö A, Hammar N, Dammström BG, Johansson M, Eliasch H. Cancer incidence in airline cabin crew: experience from Sweden. Occup Environ Med. 2003;60:810-814. http:// dx.doi.org/10.1136/oem.60.11.810
- Rafnsson V, Tulinius H, Jónasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control. 2001;12:95-101. http://dx.doi.org/10.1023/A:1008983416836
- Reynolds P, Cone J, Layefsky M, Goldberg DE, Hurley S. Cancer incidence in California flight attendants (United States). Cancer Causes Control. 2002;13:317-324. http:// dx.doi.org/10.1023/A:1015284014563
- 24. National Research Council, Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Health Risks from Exposure to Low Levels of Ionizing Radiation BEIR VII Phase 2. Washington, DC: National Academies Press; 2006.
- Land CE, Hayakawa N, Machado SG, Yamada Y, Pike MC, Akiba S, et al. A case-control interview study of breast cancer among Japanese A-bomb survivors. II. Interactions with radiation dose. Cancer Causes Control. 1994;5:167-176. http:// dx.doi.org/10.1007/BF01830263
- Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168:1-64. http://dx.doi.org/10.1667/RR0763.1
- Chapman DP, Wheaton AG, Perry GS, Sturgis SL, Strine TW, Croft JB. Household demographics and perceived insufficient sleep among US adults. J Community Health. 2012;37:344-349. http://dx.doi.org/10.1007/s10900-011-9451-x
- Hansen J, Lassen C. Nested case-control study of night shift work and breast cancer among women in the Danish military. Occup Environ Med. 2012;69:551-556. http://dx.doi. org/10.1136/oemed-2011-100240

Received for publication: 24 February 2016



Original article

Scand J Work Environ Health 2016;42(6):538-546

doi:10.5271/sjweh.3586

Breast cancer incidence among female flight attendants: exposure-response analyses

by Pinkerton LE, Hein MJ, Anderson JL, Little MP, Sigurdson AJ, Schubauer-Berigan MK

In a cohort of 6093 female flight attendants, breast cancer incidence was not associated with cumulative exposure to cosmic radiation or two metrics of circadian rhythm disruption. Positive exposure-response relations were observed only in the small subset of the cohort with parity of three or more. Cautious interpretation of the findings in women with high parity is warranted.

Affiliation: Industrywide Studies Branch, Division of Surveillance, Hazard Evaluations, and Field Studies, National Institute for Occupational Safety and Health, 1090 Tusculum Ave., R-15, Cincinnati, OH 45226, USA. lep5@cdc.gov

Refers to the following text of the Journal: 2003;29(5):0

Key terms: airline attendant; breast cancer; cancer; circadian rhythm disruption; cohort study; cosmic ionizing radiation; exposure; exposure-response; female; female flight attendant; flight attendant

This article in PubMed: www.ncbi.nlm.nih.gov/pubmed/27551752

Additional material

Please note that there is additional material available belonging to this article on the *Scandinavian Journal of Work, Environment & Health* -website.